Business Context and Reporting Period
This Form 8-K was filed by Zimmer Biomet Holdings, Inc. on February 4, 2022. The report primarily addresses two events: the announcement of financial results for the quarter and year ended December 31, 2021, and the Board of Directors' approval of a corporate separation.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing specific financial results for the fourth quarter and full year 2021. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the incorporated press release for these figures.
Material Changes and Corporate Actions
The most significant material change reported is the approved separation of the Company's spine and dental businesses into a new independent entity named ZimVie. Key details include:
- Separation Structure: Distribution of 80.3% of ZimVie common stock to Zimmer Biomet stockholders.
- Dividend Ratio: One share of ZimVie common stock for every ten shares of Zimmer Biomet common stock held.
- Record Date: February 15, 2022.
- Effective Date: March 1, 2022.
- Retained Interest: Zimmer Biomet will retain 19.7% of ZimVie's outstanding shares.
- Fractional Shares: Stockholders will receive cash in lieu of fractional shares.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential separation and distribution. Management notes that the completion of the Separation and Distribution is subject to the satisfaction or waiver of certain conditions. The document explicitly disclaims any obligation to update forward-looking statements and highlights risks that the separation may not be consummated on anticipated terms.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q4 and full-year 2021 financial metrics (revenue, earnings, cash flow) not detailed in this summary.
- Confirm the Record Date of February 15, 2022, to determine eligibility for the ZimVie stock distribution.
- Verify the conditions precedent for the Separation and Distribution as described in ZimVie's Form 10 Registration Statement.
- Assess the impact of retaining a 19.7% stake in ZimVie on Zimmer Biomet's future consolidated financial statements.